A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.

Nonalcoholic steatohepatitis arising from Western diet and lifestyle is characterized by accumulation of fat in liver causing inflammation and fibrosis. It evolves as serious health burden with alarming incidence, but there is no satisfying pharmacological therapy to date. Considering the disease's multifactorial nature, modulation of multiple targets might provide superior therapeutic efficacy. In particular, farnesoid X receptor (FXR) activation that revealed antisteatotic and antifibrotic effects in clinical trials combined with inhibition of soluble epoxide hydrolase (sEH) as anti-inflammatory strategy promises synergies. To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory activity. Merging known pharmacophores and systematic exploration of the structure-activity relationship on both targets produced dual modulators with low nanomolar potency. Extensive in vitro characterization confirmed high dual efficacy in cellular context combined with low toxicity, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets in vivo.

[1]  Manfred Schubert-Zsilavecz,et al.  Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. , 2012, Future medicinal chemistry.

[2]  K. Tomer,et al.  The Cytochrome P450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease , 2014, PloS one.

[3]  M. Wang,et al.  EETs/sEH in diabetes and obesity-induced cardiovascular diseases. , 2016, Prostaglandins & other lipid mediators.

[4]  M. Schubert-Zsilavecz,et al.  Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008–present) , 2012, Expert opinion on therapeutic patents.

[5]  Richard Morphy,et al.  Designed Multiple Ligands. An Emerging Drug Discovery Paradigm , 2006 .

[6]  P. Dawson,et al.  Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives , 2016, Hepatology.

[7]  B. Hammock,et al.  Soluble Epoxide Hydrolase Inhibitor Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Improves Survival in Mice , 2017, Shock.

[8]  G. Schneider,et al.  Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist. , 2014, Journal of medicinal chemistry.

[9]  B. Hammock,et al.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. , 2012, Journal of medicinal chemistry.

[10]  Paul D. Jones,et al.  Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. , 2005, Analytical biochemistry.

[11]  J. Boyer,et al.  Bile salt transporters: molecular characterization, function, and regulation. , 2003, Physiological reviews.

[12]  J. Boyer,et al.  Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations. , 2014, Molecular aspects of medicine.

[13]  H. Bonkovsky,et al.  Recent insights into the biological functions of liver fatty acid binding protein 1 , 2015, Journal of Lipid Research.

[14]  K. Tomer,et al.  The Cytochrome P 450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease , 2014 .

[15]  Ewgenij Proschak,et al.  Nonacidic Farnesoid X Receptor Modulators. , 2017, Journal of medicinal chemistry.

[16]  Mary E Rinella,et al.  Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.

[17]  C. Wheelock,et al.  Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. , 2002, Biochemical pharmacology.

[18]  Om Silakari,et al.  Multifunctional compounds: smart molecules for multifactorial diseases. , 2014, European journal of medicinal chemistry.

[19]  Janosch Achenbach,et al.  Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. , 2012, Biochemical pharmacology.

[20]  R. Savkur,et al.  Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor. , 2005, Biochemical and biophysical research communications.

[21]  A. Moschetta,et al.  Tissue-specific actions of FXR in metabolism and cancer. , 2015, Biochimica et biophysica acta.

[22]  G. Costantino,et al.  Molecular dynamics simulation of the ligand binding domain of farnesoid X receptor. Insights into helix-12 stability and coactivator peptide stabilization in response to agonist binding. , 2005, Journal of medicinal chemistry.

[23]  S. Fiorucci,et al.  Farnesoid X receptor: from structure to potential clinical applications. , 2005, Journal of medicinal chemistry.

[24]  G. Schneider,et al.  Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties. , 2015, Bioorganic & medicinal chemistry.

[25]  J. Lehmann,et al.  Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.

[26]  Philippe Lehert,et al.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.

[27]  Sandra K. Wittmann,et al.  N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators. , 2016, Journal of medicinal chemistry.

[28]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[29]  B. Hammock,et al.  Inhibition of Soluble Epoxide Hydrolase Attenuates High-Fat-Diet–Induced Hepatic Steatosis by Reduced Systemic Inflammatory Status in Mice , 2012, PloS one.

[30]  M. Makishima,et al.  Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor* , 2001, The Journal of Biological Chemistry.

[31]  L. Moore,et al.  Identification of a chemical tool for the orphan nuclear receptor FXR. , 2000, Journal of medicinal chemistry.

[32]  Yuan Zhang,et al.  Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction. , 2013, International journal of cardiology.

[33]  N. Chalasani,et al.  Pharmacotherapy for Nonalcoholic Fatty Liver Disease , 2015, Seminars in Liver Disease.

[34]  M. Schubert-Zsilavecz,et al.  SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound. , 2016, Future medicinal chemistry.

[35]  A. Sanyal.  Novel therapeutic targets for steatohepatitis. , 2015, Clinics and research in hepatology and gastroenterology.

[36]  K. Lindor,et al.  Recent advances in the development of farnesoid X receptor agonists. , 2015, Annals of translational medicine.

[37]  S. Mudaliar,et al.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. , 2013, Gastroenterology.

[38]  D. Steinhilber,et al.  NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor , 2015, Scientific Reports.

[39]  M. Schubert-Zsilavecz,et al.  Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma. , 2006, Planta medica.

[40]  K. Cusi,et al.  Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[41]  G. Bedogni,et al.  Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease , 2013, PloS one.

[42]  L. Adorini,et al.  Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. , 2012, Drug discovery today.

[43]  G. Schneider,et al.  Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR). , 2014, Bioorganic & medicinal chemistry.

[44]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[45]  D. Steinhilber,et al.  Functional characterization of vitamin D responding regions in the human 5-Lipoxygenase gene. , 2007, Biochimica et biophysica acta.

[46]  Jasmine Chen,et al.  Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.

[47]  Bacterial Expression and HTS Assessment of Soluble Epoxide Hydrolase Phosphatase , 2016, Journal of biomolecular screening.

[48]  Bruce D Hammock,et al.  Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. , 2004, Biochemistry.

[49]  J. Peters.  Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.

[50]  B. Hammock,et al.  Soluble epoxide hydrolase: gene structure, expression and deletion. , 2013, Gene.

[51]  M. Schubert-Zsilavecz,et al.  Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands. , 2015, Bioorganic & medicinal chemistry.

[52]  John D Imig,et al.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology. , 2012, Physiological reviews.

[53]  Tian Liu,et al.  Soluble Epoxide Hydrolase Inhibitor Suppresses the Expression of Triggering Receptor Expressed on Myeloid Cells-1 by Inhibiting NF-kB Activation in Murine Macrophage , 2016, Inflammation.

[54]  K. Tomer,et al.  Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity , 2014, Journal of Lipid Research.

[55]  G. Poropat,et al.  Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options , 2015, Drug design, development and therapy.

[56]  Richard Morphy,et al.  Designing multiple ligands - medicinal chemistry strategies and challenges. , 2009, Current pharmaceutical design.